Journal of drugs in dermatology : JDD · 2026
Atopic Dermatitis Flare Following Initiation of Nemolizumab.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Burke Olivia M, Beer Jacob, Elman Scott A
Аннотация
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by intense pruritus and episodic flares. While nemolizumab, an interleukin-31 (IL-31) inhibitor, has demonstrated efficacy in reducing itch severity, its broader effects on skin inflammation are not fully understood.
CASE PRESENTATION: We describe a 49-year-old male with longstanding, treatment-resistant AD who began off-label therapy with nemolizumab. Within weeks of initiation, he developed a new pruritic vesiculobullous eruption localized to the palms, clinically and histologically consistent with dyshidrotic eczema. His prior AD lesions remained stable, but the new eruption prompted temporary discontinuation of nemolizumab.
INTERVENTION AND OUTCOME: The patient was treated with intravenous corticosteroids, resulting in significant improvement of the dyshidrotic eczema.
CONCLUSION: This case highlights the potential for nemolizumab to exacerbate AD in some patients, emphasizing the need for caution and further research on its inflammatory effects and safety in real-world settings.
CASE PRESENTATION: We describe a 49-year-old male with longstanding, treatment-resistant AD who began off-label therapy with nemolizumab. Within weeks of initiation, he developed a new pruritic vesiculobullous eruption localized to the palms, clinically and histologically consistent with dyshidrotic eczema. His prior AD lesions remained stable, but the new eruption prompted temporary discontinuation of nemolizumab.
INTERVENTION AND OUTCOME: The patient was treated with intravenous corticosteroids, resulting in significant improvement of the dyshidrotic eczema.
CONCLUSION: This case highlights the potential for nemolizumab to exacerbate AD in some patients, emphasizing the need for caution and further research on its inflammatory effects and safety in real-world settings.